Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
LONDON - Haleon plc (LSE/NYSE: HLN), a global leader in consumer health, has announced an agreement with Pfizer Inc. (NYSE:PFE) to buy back approximately £170 million worth of its ordinary shares. This transaction is contingent on the completion of Pfizer’s accelerated bookbuild offering to institutional investors, which was also announced today.
The off-market purchase by Haleon is part of a larger £500 million share buyback initiative for 2025, which the company disclosed on February 27, 2025. The shares acquired from Pfizer will be cancelled as per Haleon’s intention, which aligns with the company’s capital allocation strategy.
Haleon’s agreement stipulates that the purchase price per ordinary share will match the offering price set by Pfizer in the Proposed Offering, provided it does not exceed the closing price of Haleon’s shares on the London Stock Exchange (LON:LSEG) on the day of the announcement.
The completion of this transaction is poised to reduce the number of Haleon’s shares in circulation, potentially impacting the company’s stock value per remaining share. The exact details of the share price and the number of shares involved in the transaction will be disclosed following the conclusion of Pfizer’s offering.
Haleon’s portfolio includes recognized brands such as Advil, Sensodyne, and Centrum, and the company has positioned itself as a dedicated player in the consumer health sector, focusing on categories like Oral Health, Pain Relief, and Vitamins, Minerals, and Supplements (VMS).
This news comes as part of a broader trend where companies repurchase their own shares as a way to return value to shareholders. Share buybacks can also reflect a company’s confidence in its financial health and future prospects.
The information regarding this proposed off-market purchase and share buyback initiative is based on a press release statement from Haleon plc. Further developments will be reported following the announcement of the results of Pfizer’s Proposed Offering.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.